It could take three or four years before the results of the larger trials are known, Eliav Barr, Merck’s head of global clinical development and chief medical officer, said in an interview.

Source: https://www.shorenewsnetwork.com/2023/04/16/moderna-merck-cancer-vaccine-plus/

“It is a regrettable possibility that these children are (casualties) of Merck’s vaccine,” he wrote.

Source: https://www.pressherald.com/2023/06/25/opinion-robert-f-kennedy-jr-is-a-threat-to-your-health-and-our-democracy/

Keytruda — provider of 35% of Merck’s revenue over the last three years — and Bristol’s Opdivo will both become potential candidates for negotiations in 2028.

Source: https://time.com/6308892/drug-price-negotiations/

Merck’s global sales were up for the most recently reported quarter, Q3, with EPS rising 4% (see slide 6).

Source: https://seekingalpha.com/article/4567353-merck-stock-buy-poised-to-outperform-2023?source=feed_all_articles

Merck’s profit margin has averaged about 25% over the last two years.

Source: https://www.latimes.com/business/story/2023-06-15/column-merck-says-its-being-coerced-into-negotiating-its-drug-prices-with-medicare-thats-nonsense

Trefis estimates Merck’s Q1 2023 revenues to be $13.9 billion, reflecting a 13% y-o-y decline and slightly above the $13.8 billion consensus estimate.

Source: https://www.forbes.com/sites/greatspeculations/2023/04/26/earnings-beat-in-the-cards-for-merck-stock/